Results 191 to 200 of about 191,066 (329)

Cardiac conduction system in rheumatic heart disease.

open access: yesThe Indian journal of medical research, 1982
P, Chopra, U, Sabherwal
openaire   +1 more source

Nanomaterial‐Based Muscle Cell/Neural Tissue Biohybrid Robots: From Actuation to Biomedical Applications

open access: yesAdvanced Robotics Research, EarlyView.
Muscle cell‐based biohybrid robot using nanomaterials for function enhancement and neural function for biomedical applications. Biohybrid robotics, an emerging field combining biological tissues with artificial systems, has made significant progress in developing various biohybrid constructs, including muscle‐cell‐driven biorobots and microbots.
Minkyu Shin   +4 more
wiley   +1 more source

Sleep Alters the Velocity of Physiological Brain Pulsations in Humans

open access: yesAdvanced Science, EarlyView.
Sleep alters I/CSF oscillatory flow, driven by increased respiratory (29%) and vasomotor pulsation (21%) velocities, while cardiovascular pulsations decreased by (22%). Velocity is quantified using optical flow analysis of MREG data. Spectral power increases alongside these pulsations (spatial correlation, r = 0.35 and r = 0.39, respectively ...
Ahmed Elabasy   +13 more
wiley   +1 more source

DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut

open access: yesAdvanced Science, EarlyView.
Dopamine receptor D2 (DRD2) deficiency disrupts epithelial barrier integrity in both the gut and pituitary gland, facilitating translocation of gut‐derived Escherichia coli into pituitary tissue. Intratumoral E. coli are phagocytosed by microglia, triggering GSDMD‐dependent pyroptosis and HMGB1 release, which subsequently activates MAPK signaling to ...
Xian‐jun Su   +16 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy